Grace Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Grace Therapeutics, Inc. (GRCE) on June 1, 2026. The report discloses the departure of a senior officer and the execution of a subsequent consulting arrangement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contractual agreements rather than financial performance.
Material Changes
- Departure of Officer: Carrie D'Andrea ceased serving as Vice President of Clinical Operations and ended her employment effective June 5, 2026.
- Consulting Arrangement: Ms. D'Andrea entered into a twelve-month Consulting Agreement effective June 5, 2026, to provide services at a rate of $250 per hour.
- Equity Vesting: Stock option awards under the Company's equity plans will continue to vest and remain exercisable during the consulting term, provided services are rendered. A 90-day post-termination exercise window applies.
- Severance: Ms. D'Andrea is entitled to severance benefits consistent with her Letter Agreement, conditioned on the release of claims and compliance with non-competition and non-solicitation covenants.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or new risk factors. The primary contingency noted is the execution of the Separation Agreement, which the Company intends to file in an amendment to this report or a subsequent filing once executed.
Investor Verification Checklist
- Verify the terms of the Separation Agreement once filed to confirm specific severance amounts and conditions.
- Review the impact of the Vice President of Clinical Operations departure on ongoing clinical trial timelines.
- Confirm the total potential equity compensation expense related to the continued vesting of Ms. D'Andrea's options under the consulting arrangement.
- Monitor for any future filings regarding the execution of the Separation Agreement.